Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics

Movement Disorders

Volumn 30, Issue 1, 2015, Pages 64-72

  Lewitt, Peter A ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbidopa; Levodopa; Parkinson's disease; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DOPAMINE; LEVODOPA; ANTIPARKINSON AGENT;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG HALF LIFE; DRUG TRANSPORT; HUMAN; MAXIMUM PLASMA CONCENTRATION; PARKINSON DISEASE; PLASMA CLEARANCE; PRIORITY JOURNAL; REVIEW; STRIATE CORTEX; SUSTAINED RELEASE FORMULATION; URINARY EXCRETION; VOLUME OF DISTRIBUTION; BRAIN; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANTIPARKINSON AGENTS; BRAIN; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84940452643     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26082     Document Type: Review

References (78)

1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
2. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism: chronic treatment with l-dopa. N Engl J Med 1969;280:337-345.
3. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: the second consensus meeting. Mov Disord 2004;19:997-1005.
4. Carlsson A, Lindqvist M, Magnusson T. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957:180:1200.
5. Hornykiewicz O. A brief history of levodopa. J Neurol 2010;257(Suppl 2):S249-S252.
6. Oster KA, Sorkin SZ. The effects of intravenous injection of L-dopa upon blood pressure. Proc Soc Exp Biol Med 1942;51:67-71.
7. Holtz P, Credner K, Kroneberg G. Über das sympathetikomimetische pressorische Prinzip des Hirns ("Urosympathin"). Arch Exp Path Pharmak 1947;204:28-243.
8. LeWitt PA. The pharmacology of levodopa in treatment of Parkinson disease: an update. In: Calne DB, ed. Drugs for the Treatment of Parkinson's Disease. Handbook of Experimental Pharmacology, vol 88. Berlin: Springer-Verlag; 1989:325-384.
9. Hornykiewicz O. How does L-dopa work? In Barbeau A, McDowell FH, eds. L-dopa and Parkinsonism. Philadelphia: FA Davis; 1970:393-399.
10. Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Bishop C. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat. Behav Brain Res 2014;270:75-85.
11. Rommelfanger KS, Weinshenker D. Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 2007;74:177-190.
12. Hefti F, Enz A, Melamed E. Partial lesions of the nigrostriatal pathway in the rat: acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology 1985;24:19-23.
13. Misu Y, Kitahama K, Goshima U. L-3, 4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system. Pharmacol Ther 2003;97:117-137.
14. Misu Y, Goshima Y. DOPA as a neurotransmitter candidate. In: Misu Y, Goshima Y, eds. Neurobiology of DOPA as a Neurotransmitter. Boca Raton, FL: CRC Press; 2006:23-34.
15. King JM, Muthian G, Mackey V, Smith M, Charlton C. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease. Life Sci 2011;89:638-643.
16. Newcomer TA, Rosenberg PA, Aizenman E. Iron-mediated oxidation of 3, 4-dihydroxyphenylalanine to an excitotoxin. J Neurochem 1995;64:1742-1748.
17. Guatteo E, Yee A, McKearney J, et al. Dual effects of L-DOPA on nigral dopaminergic neurons. Exp Neurol 2013;247:582-594.
18. Aureli C, Cassano T, Masci A, et al. 5-S-cysteinyldopamine neurotoxicity: influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease. J Neurosci Res 2014;92:347-358.
19. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
20. Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RS. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986;20:258-262.
21. Lee ES, Chen H, King J, Charlton C. The role of 3-O-methyldopa in the side effects of L-DOPA. Neurochem Res 2008;33:401-411.
22. Kaakkola S. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. Int Rev Neurobiol 2010;95:207-225.
23. Nutt JG, Woodward WR, Anderson JL. Effect of carbidopa on pharmacokinetics of intravenously administered levodopa: implications for mechanism of action of carbidopa in the treatment of Parkinsonism. Ann Neurol 1985;13:537-544.
24. Cedarbaum JM, Kutt H, Dhar AK, Watkins S, McDowell FH. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol 1986;9:153-159.
25. Ward CD, Trombley IK, Calne DB, Kopin IJ. L-dopa decarboxylation in chronically treated patients. Neurology 1984;34:198-201.
26. Dingemanse J, Kleinbloesem CH, Zürcher G, et al. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol 1997;44:41-48.
27. Tanaka H, Kannari K, Maeda T, et al. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999;10:631-634.
28. Hefti F, Melamed E, Wurtman RJ. The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther 1981;217:189-197.
29. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008;70:1980-1983.
30. Mittermeyer G, Christine CW, Rosenbluth KH, et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 2012;23:377-381.
31. Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet Neurol 2014;383:1138-1146.
32. LeWitt PA. MAO-B inhibitor know-how: back to the pharm. Neurology 2009;72:152-157.
33. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006;45:109-136.
34. LeWitt PA, Jennings D, Lyons KE, et al. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov Disord 2009;24:1319-1324.
35. Melamed E, Bitton V, Zelig O. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology 1986;36:100-103.
36. Yeh YC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(11 Suppl 2):25-38.
37. Bredberg E, Tedroff J, Aquilonius SM, et al. Pharmokinetics and effects of levodopa in advanced Parkinson's disease. Eur J Clin Pharmacol 1990;39:385-389.
38. LeWitt PA, Nelson MV, Berchou RC, et al. Controlled release carbidopa/levodopa (Sinemet 50/200 CR-4). Clinical, pharmacokinetic, and pharmacodynamic studies. Neurology 1989;39(11 Suppl 2):45-53.
39. Cedarbaum JM, Kutt H, McDowell FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 1989;39(11 Suppl 2):38-44.
40. Othman AA, Dutta S. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. Br J Clin Pharmacol 2014;78:94-105.
41. Triggs EJ, Charles BG, Contin M, et al. Population pharmacokinetics of oral levodopa in parkinsonian patients. Eur J Clin Pharmacol 1996;51:59-67.
42. Jorga K, Banken L, Fotteler B, Snell JL, Steimer JL. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone. Clin Pharmacol Ther 2000;67:610-620.
43. Chan PLS, Nutt JG, Holford NHG. Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. J Pharmacokin Pharmacodynam 2005;32:307-331.
44. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first four years of therapy. Ann Neurol 2002;51:686-693.
45. Contin M, Riva R, Martinelli P, et al. Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 1993;43:367-371.
46. Kompoliti K, Adler CH, Raman R, et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 2002;58:1418-1422.
47. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992;42:726-732.
48. Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 2001;16:1041-1047.
49. Robertson DR, Renwick AG, Wood ND, et al. The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol 1990;29:47-53.
50. Rees K, Stowe R, Patel S, et al. Helicobacter pylori eradication for Parkinson's disease. Cochrane Database Syst Rev 2011;11:CD008453.
51. Rahne KE, Tagesson C, Nyholm D. Motor fluctuations and Helicobacter pylori in Parkinson's disease. J Neurol 2013;260:2974-2980.
52. Narozańska E, Bialecka M, Adamiak-Giera U, et al. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection. Clin Neuropharmacol 2014;37:96-99.
53. Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013;28:1241-1249.
54. Nyholm D, Lennernas H, Gomes-Trolin C, et al. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 2002;25:89-96.
55. Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 1984;310:483-488.
56. Robertson DR, Wood ND, Everest H, et al. The effect of age on the pharmacokinetics of levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 1989;28:61-69.
57. Contin M, Riva R, Martinelli P, et al. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 1991;41:463-466.
58. Nelson MV, Berchou RC, LeWitt PA, et al. Pharmacokinetic and pharmacodynamic modeling of levodopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet Clin Neuropharmacol 1989;12:91-97.
59. Contin M, Riva R, Albani F, et al. Pharmacokinetic optimization in the treatment of Parkinson's disease. Clin Pharmacokinet 1996;30:463-481.
60. Nelson MV, Berchou RC, LeWitt PA, et al. Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa /levodopa (Sinemet CR4) in Parkinson's disease. Neurology 1990;40:70-74.
61. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-239.
62. Zappia M, Oliveri RL, Montesanti R, et al. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology 1999;52:763-767.
63. Anderson E, Nutt J. The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications. Parkinsonism Relat Disord. 2011;17:587-592.
64. Quattrone A, Zappia M, Agualia U, et al. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol 1995;38:389-395.
65. Doller HJ, Connor JD. Changes in neocortical dopamine concentrations in response to levodopa infusions. J Neurochem 1980;34:1264-1269.
66. Cenci MA, Tranberg A, Andersson M, Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 1999;94:515-527.
67. Ebihara K, Ishida Y, Takeda R, et al. Differential expression of FosB, c-Fos, and Zif268 in forebrain regions after acute or chronic L-DOPA treatment in a rat model of Parkinson's disease. Neurosci Lett 2011;496:90-94.
68. Riverol M, Ordóñez C, Collantes M, et al. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway. Neurobiol Dis 2014;62:250-259.
69. Tremblay PL, Bedard MA, Langlois D et al. Movement chunking during sequence learning. Is a dopamine-dependent process: a study conducted in Parkinson's disease. Exp Brain Res 2010; 205:375-385.
70. LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-2476.
71. Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12:346-356.
72. LeWitt PA, Huff FJ, Hauser R, et al. Double-blind study of an actively-transported levodopa prodrug, XP21279, in Parkinson disease. Mov Disord 2014;29:75-82.
73. Stocchi F, Marconi S. Factors associated with motor fluctuations and dyskinesia in Parkinson disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Clin Neuropharmacol 2010;33:198-203.
74. LeWitt PA, Giladi N, Gurevich T, et al. Accordion Pill carbidopa/levodopa (AP CD/LD) for treatment of advanced Parkinson's disease (PD). Mov Disord. 2014;29(suppl 1): S248.
75. Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. Clin Neuropharmacol. 012;35:67-72.
76. Freed MI, Moore JA, Batycky R, Tia D-F, CVT-301-002 Study Investigators. Pharmacokinetics (PK) following inhaled levodopa delivery with CVT-301: Rapid augmentation of systemic levodopa (LD) levels and improvement in motor function in PD patients with motor fluctuations. Mov Disord. 2014;29(suppl 1):S239.
77. Caraco Y, Oren S, LeWitt P. Constant therapeutic levodopa (LD) plasma concentrations maintained by continuous subcutaneous (SC) administration of ND-0612, a novel formulation of LD/carbidopa (CD). Mov Disord 2013;28(suppl 1):S162.
78. Cilia R, Akpalu A, Sarfo FS, et al. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain 2014; 137; 2731-2742.